A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery - The Fibrin Pad Liver Study

Omrix Biopharmaceuticals Ltd0 个研究点目标入组 200 人开始时间: 2010年6月22日最近更新: 2012年10月2日

适应症

试验速览

暂无简介。

•1. Subjects > 18 years of age, requiring elective or urgent open hepatic surgery
•2. Presence of an appropriate bleeding parenchymal Target Bleeding Site (TBS) as identified intra-operatively by the surgeon.
•3. Subjects must be willing to participate in the study, and provide written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

•1. Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure;
•2. TBS is from large defects in arteries or vein where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the Fibrin Pad to blood flow and pressure during healing and absorption of the product;
•3. TBS with major arterial bleeding requiring suture or mechanical ligation;
•4. Subjects admitted for trauma surgery;
•5. Subject is a transplant patient for fulminant hepatic failure;
•6. Subject with TBS within an actively infected field;
•7. Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine.
•8. Subjects with known intolerance to blood products or to one of the components of the study product;
•9. Subjects who are known, current alcohol and / or drug abusers;
•10. Subjects who have participated in another investigational drug or device research study within 30 days of surgery;
•11. Female subjects who are pregnant or nursing.

发起方